Evidence map›Paper›PMID 39215330›Full record

ArticleOrphanet journal of rare diseases2024

Leber hereditary optic neuropathy in Slovenia: quality of life and costs from patient perspective.

Marko Hawlina, Lea Kovač, Katarína Breciková, Jan Žigmond, Vladimír Rogalewicz, Aleš Tichopád, Martin Višňanský, Ivana Šarkanová

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marko Hawlina *Eye Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Lea Kovač *Eye Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Katarína BrecikováCEEOR s.r.o., Prague, Czechia. katarina.brecikova@ceeor.com.ORCID 0000-0002-3783-7416
Jan ŽigmondDepartment of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University Prague, Kladno, Czechia.
Vladimír RogalewiczDepartment of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University Prague, Kladno, Czechia.
Aleš TichopádDepartment of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University Prague, Kladno, Czechia.
Martin VišňanskýDepartment of Pharmacy and Social Pharmacy, University of Veterinary Medicine and Pharmacy Košice, Košice, Slovakia.
Ivana ŠarkanováCEEOR s.r.o., Prague, Czechia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLeber hereditary optic neuropathy (LHON) is the most commonly diagnosed mitochondrial disorder, resulting in colour vision abnormalities and rapid but painless deterioration of central vision. While numerous studies have assessed the impact of LHON on the quality of life (QoL) of LHON patients, the financial impact of the disease remains unexplored. This study attempts to calculate both the direct non-medical costs and the indirect costs associated with productivity losses experienced by people with LHON and their unpaid caregivers in Slovenia, in addition to assessing their QoL. Due to the rarity of the disease, the study involved a small sample size, which is important to note for interpreting the results.

methodsThe analysis was conducted on nine adult participants diagnosed with LHON, representing one-third of the total number of known Slovenian patients with this condition. To thoroughly assess the economic and social impact of LHON, tailored questionnaires were designed to collect information on demographics, socioeconomic status, LHON severity, and associated non-medical and indirect costs.

resultsThe mean age of the study participants was 48.8 years (SD 13.3; n = 9). The annual productivity loss attributable to LHON, taking both absenteeism and relative presenteeism into account, was calculated to be EUR 11,608 per person affected. The mean VFQ-25 score, a measure of vision-related quality of life, for adult LHON patients was 30.4 (SD 12.9).

conclusionThe findings highlight the significant economic and social burden of LHON on patients and their families. Ensuring prompt, accurate diagnosis, access to treatment, financial support, and psychological counselling and services are critical to helping individuals cope with and mitigate the profound challenges of vision loss and living with LHON.

Indexed as

Optic Atrophy, Hereditary, LeberQuality of LifeAdultAgedCost of IllnessFemaleHumansMaleMiddle AgedSloveniaSurveys and QuestionnairesAbsenteeismLHONProductivity lossQuality of lifeSocioeconomic burden

Identifiers

PMID39215330
PMCPMC11365147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.